Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
INNV vs OSCR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
INNV vs OSCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Medical - Healthcare Plans |
| Market Cap | $1.10B | $5.41B |
| Revenue (TTM) | $946M | $13.30B |
| Net Income (TTM) | $-22M | $-39M |
| Gross Margin | 14.8% | 17.4% |
| Operating Margin | 1.5% | 0.1% |
| Forward P/E | 32.0x | 34.7x |
| Total Debt | $101M | $430M |
| Cash & Equiv. | $64M | $2.77B |
INNV vs OSCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| InnovAge Holding Co… (INNV) | 100 | 31.3 | -68.7% |
| Oscar Health, Inc. (OSCR) | 100 | 77.6 | -22.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INNV vs OSCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INNV has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.66
- Lower volatility, beta 1.66, Low D/E 38.4%, current ratio 1.07x
- Beta 1.66, current ratio 1.07x
OSCR is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 27.5%, EPS growth -18.7%, 3Y rev CAGR 41.6%
- -40.0% 10Y total return vs INNV's -66.6%
- 27.5% revenue growth vs INNV's 11.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.5% revenue growth vs INNV's 11.8% | |
| Value | Lower P/E (32.0x vs 34.7x) | |
| Quality / Margins | -0.3% margin vs INNV's -2.3% | |
| Stability / Safety | Beta 1.66 vs OSCR's 1.84, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +147.9% vs OSCR's +22.6% | |
| Efficiency (ROA) | -0.6% ROA vs INNV's -4.1% |
INNV vs OSCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
INNV vs OSCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
OSCR leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
OSCR is the larger business by revenue, generating $13.3B annually — 14.1x INNV's $946M. Profitability is closely matched — net margins range from -0.3% (OSCR) to -2.3% (INNV). On growth, OSCR holds the edge at +52.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $946M | $13.3B |
| EBITDAEarnings before interest/tax | $4M | $40M |
| Net IncomeAfter-tax profit | -$22M | -$39M |
| Free Cash FlowCash after capex | $39M | $2.8B |
| Gross MarginGross profit ÷ Revenue | +14.8% | +17.4% |
| Operating MarginEBIT ÷ Revenue | +1.5% | +0.1% |
| Net MarginNet income ÷ Revenue | -2.3% | -0.3% |
| FCF MarginFCF ÷ Revenue | +4.1% | +21.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.5% | +52.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -161.3% | +125.0% |
Valuation Metrics
INNV leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.1B | $5.4B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $3.1B |
| Trailing P/EPrice ÷ TTM EPS | -36.73x | -12.35x |
| Forward P/EPrice ÷ next-FY EPS est. | 32.03x | 34.65x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.28x | 0.46x |
| Price / BookPrice ÷ Book value/share | 4.16x | 5.58x |
| Price / FCFMarket cap ÷ FCF | 41.22x | 5.11x |
Profitability & Efficiency
INNV leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
OSCR delivers a -3.3% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-8 for INNV. INNV carries lower financial leverage with a 0.38x debt-to-equity ratio, signaling a more conservative balance sheet compared to OSCR's 0.44x. On the Piotroski fundamental quality scale (0–9), INNV scores 6/9 vs OSCR's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -8.2% | -3.3% |
| ROA (TTM)Return on assets | -4.1% | -0.6% |
| ROICReturn on invested capital | -6.8% | — |
| ROCEReturn on capital employed | -7.1% | -25.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.38x | 0.44x |
| Net DebtTotal debt minus cash | $37M | -$2.3B |
| Cash & Equiv.Liquid assets | $64M | $2.8B |
| Total DebtShort + long-term debt | $101M | $430M |
| Interest CoverageEBIT ÷ Interest expense | 5.96x | -0.57x |
Total Returns (Dividends Reinvested)
OSCR leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OSCR five years ago would be worth $9,271 today (with dividends reinvested), compared to $3,150 for INNV. Over the past 12 months, INNV leads with a +147.9% total return vs OSCR's +22.6%. The 3-year compound annual growth rate (CAGR) favors OSCR at 40.5% vs INNV's 7.6% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +55.7% | +39.4% |
| 1-Year ReturnPast 12 months | +147.9% | +22.6% |
| 3-Year ReturnCumulative with dividends | +24.5% | +177.5% |
| 5-Year ReturnCumulative with dividends | -68.5% | -7.3% |
| 10-Year ReturnCumulative with dividends | -66.6% | -40.0% |
| CAGR (3Y)Annualised 3-year return | +7.6% | +40.5% |
Risk & Volatility
Evenly matched — INNV and OSCR each lead in 1 of 2 comparable metrics.
Risk & Volatility
INNV is the less volatile stock with a 1.66 beta — it tends to amplify market swings less than OSCR's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OSCR currently trades 87.7% from its 52-week high vs INNV's 75.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.66x | 1.84x |
| 52-Week HighHighest price in past year | $10.68 | $23.80 |
| 52-Week LowLowest price in past year | $2.85 | $10.69 |
| % of 52W HighCurrent price vs 52-week peak | +75.7% | +87.7% |
| RSI (14)Momentum oscillator 0–100 | 50.2 | 78.5 |
| Avg Volume (50D)Average daily shares traded | 291K | 6.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates INNV as "Hold" and OSCR as "Hold". Consensus price targets imply -15.8% upside for INNV (target: $7) vs -19.7% for OSCR (target: $17).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold |
| Price TargetConsensus 12-month target | $6.80 | $16.75 |
| # AnalystsCovering analysts | 8 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.7% | 0.0% |
OSCR leads in 2 of 6 categories (Income & Cash Flow, Total Returns). INNV leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
INNV vs OSCR: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is INNV or OSCR a better buy right now?
For growth investors, Oscar Health, Inc.
(OSCR) is the stronger pick with 27. 5% revenue growth year-over-year, versus 11. 8% for InnovAge Holding Corp. (INNV). Analysts rate InnovAge Holding Corp. (INNV) a "Hold" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — INNV or OSCR?
Over the past 5 years, Oscar Health, Inc.
(OSCR) delivered a total return of -7. 3%, compared to -68. 5% for InnovAge Holding Corp. (INNV). Over 10 years, the gap is even starker: OSCR returned -40. 0% versus INNV's -66. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — INNV or OSCR?
By beta (market sensitivity over 5 years), InnovAge Holding Corp.
(INNV) is the lower-risk stock at 1. 66β versus Oscar Health, Inc. 's 1. 84β — meaning OSCR is approximately 10% more volatile than INNV relative to the S&P 500. On balance sheet safety, InnovAge Holding Corp. (INNV) carries a lower debt/equity ratio of 38% versus 44% for Oscar Health, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — INNV or OSCR?
By revenue growth (latest reported year), Oscar Health, Inc.
(OSCR) is pulling ahead at 27. 5% versus 11. 8% for InnovAge Holding Corp. (INNV). On earnings-per-share growth, the picture is similar: InnovAge Holding Corp. grew EPS -37. 5% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Over a 3-year CAGR, OSCR leads at 41. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — INNV or OSCR?
InnovAge Holding Corp.
(INNV) is the more profitable company, earning -3. 6% net margin versus -3. 8% for Oscar Health, Inc. — meaning it keeps -3. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OSCR leads at -3. 4% versus -3. 5% for INNV. At the gross margin level — before operating expenses — INNV leads at 68. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is INNV or OSCR more undervalued right now?
On forward earnings alone, InnovAge Holding Corp.
(INNV) trades at 32. 0x forward P/E versus 34. 7x for Oscar Health, Inc. — 2. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INNV: -15. 8% to $6. 80.
07Which pays a better dividend — INNV or OSCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is INNV or OSCR better for a retirement portfolio?
For long-horizon retirement investors, InnovAge Holding Corp.
(INNV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Oscar Health, Inc. (OSCR) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INNV: -66. 6%, OSCR: -40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between INNV and OSCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: INNV is a small-cap quality compounder stock; OSCR is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.